



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com)

Corp Office : 701/702 Business Square, M. A. Road, Andheri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820)

(Rs. in Lakhs)

## Statement of Standalone Audited Results for the Quarter and for the Year Ended 31 MARCH, 2015

Particulars	Quarter Ended			Year Ended	
	31-Mar-15 (Unaudited)	31-Dec-14 (Unaudited)	31-Mar-14 (Unaudited)	31-Mar-15 (Audited)	31-Mar-14 (Audited)
1 (a). Net Income from Sales / Services	917.69	899.25	1,216.04	4,739.44	6,484.06
(b). Other Operating Income	1.44	0.89	4.88	17.36	58.62
Total Income	919.13	900.14	1,220.92	4,756.80	6,542.68
2. Expenditure					
a) Consumption of Raw Materials	764.74	743.48	1,083.74	3,849.60	5,697.70
b) Changes in Stock of Finished Goods, Work-in-progress, Traded goods	43.82	42.60	(158.17)	204.58	280.00
c) Purchase of Traded Goods	0.00	0.00	63.74	216.73	63.74
d) Employee Costs	28.83	23.50	25.56	91.20	66.10
e) Depreciation	17.28	8.94	8.30	43.76	33.09
f) Other Expenditure					
(i) Manufacturing Expenses	53.76	40.56	128.08	157.28	166.34
(ii) Administration Expenses	16.22	15.60	9.89	59.65	59.99
(iii) Selling & Distribution Expenses	7.54	12.75	17.01	44.96	80.92
g) Total	932.19	887.43	1,178.15	4,667.76	6,447.88
3. Profit from Operations before Other Income, Interest and Exceptional Items	(13.06)	12.71	42.77	89.04	94.80
4. Other Income	4.90	3.93	6.50	17.41	21.26
5. Profit before Interest and Exceptional items	(8.16)	16.64	49.27	106.45	116.06
6. Interest	11.26	10.26	9.33	58.55	75.34
7. Profit after Interest but before Exceptional items	(19.42)	6.38	39.94	47.90	40.72
8. Exceptional Items	0.00	0.00	0.00	0.00	0.00
9. Profit/(Loss) from ordinary activities before tax	(19.42)	6.38	39.94	47.90	40.72
10. Tax expense (incl deferred tax)	(10.49)	4.01	5.06	16.31	16.56
11 Net Profit/(Loss) from ordinary activities after tax	(8.93)	2.37	34.88	31.59	24.16
12. Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	(8.93)	2.37	34.88	31.59	24.16
14. Paid-up Equity Share Capital	308.97	308.97	308.97	308.97	308.97
15. Reserves excluding revaluation reserves	-	-	-	1,036.51	1,004.91
16. Earnings per share					
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	(0.29)	0.08	1.13	1.02	0.78
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	(0.29)	0.08	1.13	1.02	0.78
17. Public shareholding					
-- Number of shares	1,633,715	1,638,076	1,644,269	1,633,715	1,644,269
-- Percentage of shareholding	52.88	53.02	53.22	52.88	53.22
18. Promoters and promoter group shareholding**					
a) Pledged/ Encumbered					
-- Number of shares	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00
b) Non-encumbered					
-- Number of shares	1,455,985	1,451,624	1,445,431	1,455,985	1,445,431
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	47.12	46.98	46.78	47.12	46.78



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

<b>Standalone Statement of Assets and Liabilities</b>		
<b>Particulars</b>	<b>As at 31-Mar-2015 (Audited)</b>	<b>As at 31-Mar-2014 (Audited)</b>
<b><u>EQUITY AND LIABILITIES</u></b>		
<b>SHAREHOLDERS' FUNDS:</b>		
(a) Capital	308.97	308.97
(b) Reserves and Surplus	1,036.51	1,004.91
(c) Money Received Against Share Warrants	0.00	0.00
Sub total- Shareholders' Fund	1,345.48	1,313.88
<b>SHARE APPLICATION MONEY PENDING ALLOTMENT</b>	0.00	0.00
<b>NON - CURRENT LIABILITIES</b>		
(a) Long-Term Borrowings	25.69	65.62
(b) Deferred Tax Liabilities (Net)	42.56	36.97
(c) Other Long-Term Liabilities	0.00	0.00
(d) Long-Term Provisions	0.00	0.00
Sub total- Non Current Liabilities	68.25	102.59
<b>CURRENT LIABILITIES</b>		
(a) Short-Term Borrowings	300.46	248.88
(b) Trade Payables	893.43	1,442.29
(c) Other Current Liabilities	19.22	25.31
(d) Short-Term Provisions	0.00	5.71
Sub total- Current Liabilities	1,213.11	1,722.19
<b>Total - Equity and Liabilities</b>	<b>2,626.84</b>	<b>3,138.66</b>
<b><u>ASSETS</u></b>		
<b>NON-CURRENT ASSETS</b>		
(a) Fixed Assets	722.13	750.92
(b) Non-Current Investment	0.00	0.00
(c) Deferred Tax Assets (Net)	0.00	0.00
(d) Long-Term Loans And Advances	13.10	13.21
(e) Other Non-Current Assets	41.97	20.62
Sub total- Non Current Assets	777.20	784.75
<b>CURRENT ASSETS</b>		
(a) Current Investment	0.00	0.00
(b) Inventories	447.23	748.05
(c) Trade Receivables	962.32	1,122.88
(d) Cash And Cash Equivalents	395.13	436.04
(e) Short-term loans and advances	2.58	3.00
(f) Other current assets	42.38	43.94
Sub total- Current Assets	1,849.64	2,353.91
<b>Total - Assets</b>	<b>2,626.84</b>	<b>3,138.66</b>



# Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

**Notes:**

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The above results have been taken on record by the Board of Directors at its Meeting held on Saturday, 30 May 2015 at the Corporate Office of the Company.
3. The above figures are after accounting for a net foreign exchange loss of Rs.29.92 lakhs during the year.
4. The figures of the quarter ended 31 Mar 2015 and 31 Mar 2014 are the balancing figures between the audited figures in respect of full financial years and the published (unaudited) up to the third quarter of relevant financial year.
5. Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 31 March, 2015:

Opening Balance as on	1/Jan/2015	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	31/Mar/2015	0

6. The figures for the previous period have been regrouped where necessary to conform to current period's classification.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Place : Mumbai  
Date : 30 May 2015**

**Rajesh Mehta  
Executive Director**